CoChat

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study

Nielsen, S. E., Persson, F., Frandsen, E., Sugaya, T., Hess, G., Zdunek, D., Shjoedt, K. J., Parving, H‐H., Rossing, P. · 2012 · Diabetic Medicine
Cited by 86

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 29, e184–e190 (2012) Aims Adding aldosterone receptor blockade to standard renoprotective treatment may provide additional renoprotection in patients with overt nephropathy. We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria. Methods A double‐blind, randomized, placebo‐controlled crossover study in 21 patients with Type 1 diabetes and microalbuminuria using spironolactone 25 mg or placebo once daily, for 60 days added to standard antihypertensive treatment. After each treatment period, the primary endpoint were evaluated: urinary(u)‐albumin excretion/24 hour(h) and secondary endpoints; 24 h blood pressure, glomerular filtration rate (GFR) and markers of tubular damage: urinary liver‐type fatty‐acid binding protein (LFABP), neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1). Results All patients completed the study. During spironolactone treatment, urinary albumin excretion rate was reduced by 60% (range 21–80%), from 90 mg/24 h to 35 mg/24 h (P = 0.01). Blood pressure (24 h) did not change during spironolactone treatment (P > 0.2 for all comparisons). The GFR (SD) decreased from 78 (6) mL/min/1.73 m 2 to 72 (6) mL/min/1.73 m 2 (P = 0.003). Urinary liver‐type fatty‐acid binding protein, neutrophil gelatinase‐associated lipocalin and kidney injury molecule 1 did not change during treatment (P > 0.3 for all comparisons). Treatment was well‐tolerated, but two patients had severe hyperkalaemia (plasma potassium = 5.7 mmol/l), which was sufficiently treated with diuretics and dietary intervention. Conclusions Spironolactone treatment in addition to standard renoprotective treatment lowers urinary albumin excretion in microalbuminuric patients with Type 1 diabetes, and thus may offer additional renoprotection independent of blood pressure.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03585.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 86

Metadata

Authors
Nielsen, S. E., Persson, F., Frandsen, E., Sugaya, T., Hess, G., Zdunek, D., Shjoedt, K. J., Parving, H., & Rossing, P.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2012-07-15
Volume
29
Issue
8
Pages
e184-90
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1550649928
Cited by
86
References
1
FWCI
7.22
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.